1
项与 RBMRNA-176(Guangzhou Medical University/Guangzhou Ribobio/Agna Biopharmaceutical) 相关的临床试验A Phase I/II, Randomized, Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (RBMRNA-176) in Healthy Adults Aged 18 Years and Older
The phase I/II study is to evaluate the safety and immunogenicity of SARS-COV-2 mRNA Vaccine (RBMRNA-176) at different doses in healthy subjects aged 18 years and older.
100 项与 RBMRNA-176(Guangzhou Medical University/Guangzhou Ribobio/Agna Biopharmaceutical) 相关的临床结果
100 项与 RBMRNA-176(Guangzhou Medical University/Guangzhou Ribobio/Agna Biopharmaceutical) 相关的转化医学
100 项与 RBMRNA-176(Guangzhou Medical University/Guangzhou Ribobio/Agna Biopharmaceutical) 相关的专利(医药)
100 项与 RBMRNA-176(Guangzhou Medical University/Guangzhou Ribobio/Agna Biopharmaceutical) 相关的药物交易